20
Participants
Start Date
April 9, 2021
Primary Completion Date
May 28, 2021
Study Completion Date
May 28, 2021
Afrezza Dose 1
The first dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue (RAA) insulin that the subject would normally take for the standardized meal, converted according to the guidelines provided in the current Afrezza U.S. prescribing information.
Afrezza Dose 2
The second dose of Afrezza will be based on the dose of subcutaneous rapid-acting analogue that the subject would normally take for the standardized meal, converted by multiplying their RAA dose by 2 and rounding down to the nearest Afrezza cartridge size.
AMCR Institute, Escondido
Diablo Clinical Research, Walnut Creek
Lead Sponsor
Mannkind Corporation
INDUSTRY